Moderna
MRNA
$129.06
Share price
0.58%
Change (1 day)
-0.92%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.
Moderna (MRNA) - Total liabilities
Total liabilities on the balance sheet as of March 2024 : $3.91 B
According to Moderna 's latest financial reports the company's total liabilities are $3.91 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Moderna - Total liabilities on balance sheet (from 2017 to 2024)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $4.57 B | -32.12% |
| 2022-12-31 | $6.73 B | -36% |
| 2021-12-31 | $10.52 B | 120.35% |
| 2020-12-31 | $4.77 B | 1051.92% |
| 2019-12-31 | $0.41 B | -4% |
| 2018-12-31 | $0.43 B | -5.94% |
| 2017-12-31 | $0.45 B | -20.18% |
| 2016-12-31 | $0.57 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $101.94 B | 2,505.98% | 🇺🇸 USA |
 Novartis NVS | $54.57 B | 1,295.14% | 🇨🇭 Switzerland |
 Merck MRK | $69.04 B | 1,664.83% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | $9.56 M | -99.76% | 🇺🇸 USA |
 Athersys ATHX | $43.82 M | -98.88% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | $4.04 B | 3.37% | 🇺🇸 USA |
 Arrowhead Pharmaceuticals
ARWR | $0.45 B | -88.43% | 🇺🇸 USA |